MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

ESMO 2022

European Society for Medical Oncology (ESMO) Meeting 2022 - September 9-13, 2022 / Paris, France

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

5-Year Overall Survival (OS) in Patients (pts) with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN) Treated with Xevinapant + Chemoradiotherapy (CRT) vs Placebo + CRT in a Randomized, Phase 2 Study

Bourhis | Oral #2522

Tepotinib + Osimertinib for EGFRm NSCLC with MET Amplification (METamp) After Progression on First-Line (1L) Osimertinib: Initial Results from the INSIGHT 2 Study

Mazieres | Oral #LBA52

Genomic Biomarkers in Peripheral Blood (PB) from Patients (pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

Powles | Oral #LBA74

A Phase I Study of ATR Inhibitor M1774 in Patients with Solid Tumours (DDRiver Solid Tumours 301): Part A1 Results

Yap | Oral #457MO

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results from Patients with ≥12 Months of Treatment in JAVELIN Bladder 100 (includes PLS)

Aragon-Ching | Poster #1760P

Preliminary Results from AVENANCE, an Ongoing, Noninterventional Real-world, Ambispective Study of Avelumab First-line Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (includes PLS)

Barthélémy | Poster #1757P

Clinical Potential of Circulating Tumor DNA (ctDNA)–Based Molecular Response (MR) And Baseline Blood-based Tumor Mutational Burden (bTMB) for Monitoring Response to First-Line (1L) Chemoimmunotherapy in Advanced Squamous Non-small Cell Lung Cancer (sqNSCLC)

Ciardiello | Poster #1092P

Treatment Patterns and Progression-Free Survival In MET Exon 14 (METex14) Skipping Advanced Non-small Cell Lung Cancer (aNSCLC) In Real-World Clinical Practice)

Ho | Poster #1180P

US Real-World (RW) Patient Characteristics with METex14 Skipping Advanced Non-small Cell Lung Cancer (aNSCLC)

Kelly | Poster #1182P

Factors Associated with Receipt of Systemic Treatment for Metastatic Urothelial Carcinoma (mUC) in England

Knott | Poster #1750P

Evaluating Real-world Caregiver Involvement from a Survey of Patients with Metastatic Urothelial Cancer (mUC) Receiving Systemic Anticancer Treatment In France, Germany, Italy, Spain, and the UK (Eu5)

Lapuente | Poster #CN71

Real-world Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma (mUC): Results of a Nationwide, Longitudinal, Retrospective Study in Hungary

Maráz | Poster #1756P

Phase I Study of TIGIT Inhibitor M6223 ± Bintrafusp Alfa in Patients with Metastatic/locally Advanced Unresectable Solid Tumours

Siu | Poster #750P

Tepotinib Outcomes According to Prior Therapies in Patients with MET Exon 14 (METex14) Skipping NSCLC

Smit | Poster #985P

Undertreatment Rates, Associated Factors, and Survival Among Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC): A Systematic Literature Review

Wilke | Poster #1765P

Phase II Study of Berzosertib + Topotecan in Patients with Relapsed Platinum-Resistant SCLC (DDRiver SCLC 250): Japanese Safety Run-In

Yoshida | Poster #1534P

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options:

ESMO 2022

Cookie Disclaimer

Welcome to EMD Serono Medical Information!